Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in Pseudomonas aeruginosa

Estela Ynés Valencia, Fernanda Esposito, Beny Spira, Jesús Blázquez, Rodrigo S. Galhardo
Estela Ynés Valencia
aDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernanda Esposito
bDepartment of Clinical Analysis, School of Pharmacy, University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beny Spira
aDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesús Blázquez
cInstituto de Biomedicina de Sevilla (IBIS)-CSIC, Seville, Spain
dCentro Nacional de Biotecnología-CSIC, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jesús Blázquez
Rodrigo S. Galhardo
aDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rodrigo S. Galhardo
DOI: 10.1128/AAC.02107-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Resistance to antibiotics is a global health problem. Activation of the SOS response, and the subsequent elevation in mutagenesis, contributes to the appearance of resistance mutations. Among currently used drugs, quinolones are the most potent inducers of the SOS response. In the present study, we show that amikacin inhibits ciprofloxacin-mediated SOS induction and mutagenesis in Pseudomonas aeruginosa.

TEXT

Antibiotics may cause genetic changes involving different pathways, and one of them is the induction of error-prone polymerases mediated by SOS response (1, 2). Ciprofloxacin (CIP), one of the antimicrobials of choice for the treatment of Pseudomonas aeruginosa, induces the SOS response (3–5) by interfering with gyrase or topoisomerase activity (6, 7). The SOS regulon controls 15 genes, including imuABC and dinB (4, 5), which encode error-prone polymerases (8, 9). By inducing the SOS response, ciprofloxacin increases mutagenesis (e.g., see references 10 and 11), facilitating the appearance of drug resistance.

We investigated the effect of antibiotic combinations on the SOS response and mutagenesis induced by ciprofloxacin in P. aeruginosa PAO1. recA is among the SOS-regulated genes in this organism (4, 5). To analyze the induction of the SOS response, we constructed a chromosomal PrecA-lux reporter. The regulatory region upstream from recA (−501 bp relative to the start codon) was cloned into the pUC18T-mini-Tn7T-lux-Gm plasmid (12) and transferred to P. aeruginosa for integration at attTn7, resulting in strain attTn7::PrecA-lux. The effect of antibiotics on the expression of the reporter was evaluated in solid medium using disk-based qualitative assays. The PrecA-lux strain was diluted to an optical density at 260 nm (OD600) of 0.1. Fifty microliters of this dilution was seeded on Mueller-Hinton (MH) agar, and test antibiotic disks and CIP (5 μg) disks (Sensifar-Cefar, Brazil) were placed close to one another to observe the effect of the antibiotic interaction on recA expression. Luciferase activity was detected in the ChemiDoc MP system (Bio-Rad, USA).

Amikacin (AMI), imipenem, meropenem, polymyxin B, ceftazidime, cefepime, and aztreonam were tested, representing different drug classes. We found that amikacin is not an inducer of the SOS response but is in fact a strong inhibitor of recA induction by sub-MICs of ciprofloxacin (Fig. 1A). Amikacin is an aminoglycoside derived from kanamycin (13). Aminoglycosides bind, with high affinity, to the A-site on the 16S rRNA of the 30S ribosome (14) and can cause mRNA decoding errors, block mRNA and tRNA translocation, and inhibit ribosome recycling (15).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Effect of amikacin on the transcription of PrecA-lux and mutagenesis on a solid medium. (A) Sub-MICs of ciprofloxacin induce the expression of the PrecA-lux reporter, and when the amikacin disks are in proximity to the ciprofloxacin disk, a decrease in the light ring is observed, indicating inhibition of recA induction. (B) A large number of Cipr mutants in the clearing zone can be observed when the PAO1 strain is plated on MH agar but not when the recA derivative is analyzed. Addition of a sub-MIC amikacin concentration (0.4 μg/ml) to the medium decreases the appearance of Cipr mutants. A representative result is shown for plates incubated for 72 h.

We tested whether this effect on SOS induction reflects a general antagonistic effect of both drugs, using the checkerboard assay (16), in the presence of CIP (0.0078 to 0.5 μg/ml) and AMI (0.003 to 4 μg/ml). A fractional inhibitory concentration (FIC) index of 0.6 (CIP+AMI) was observed, indicating no antagonism. Accordingly, no apparent antagonism is seen in MH agar (Fig. 1A). The MIC of amikacin (0.5 μg/ml) and ciprofloxacin (0.06 μg/ml) was determined using the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) (17).

The appearance of Cipr mutants in cells exposed to ciprofloxacin in solid medium was monitored using a previously established assay (18). Fifty microliters of cultures (OD600 = 0.1) was seeded on MH agar, and a ciprofloxacin disk (5 μg) was placed in the center of the plate and incubated at 37°C for 72 h. The wild-type strain presents a high number of resistant colonies in the clearing zone. However, when sub-MIC amikacin was added to the medium (0.4 μg/ml), a dramatic reduction in the appearance of Cipr mutants occurred (Fig. 1B). Eleven Cipr mutants were grown on plates containing 0.125 μg/ml CIP, with or without 0.4 μg/ml of amikacin, and all formed visible colonies after 24 h in both conditions (data not shown). These results rule out an inability of Cipr mutants to grow in the presence of subinhibitory levels of amikacin, suggesting that the acquisition of mutations is inhibited.

Inactivation of recA in Escherichia coli reduces mutagenicity (11) and increases the activity of a large number of antimicrobials in other bacteria (19, 20). To determine if mutations arise in a recA-dependent manner, a recA mutant strain was constructed by insertional mutagenesis. An internal region of the recA gene (from bases 90 to 594 of the coding region) was cloned into the pKNOCK-Tc suicide plasmid (21), transferred to P. aeruginosa by conjugation using the E. coli S17-1 λpir, and the integration was confirmed by PCR. The recA mutant strain shows a substantial reduction in the number of Cipr mutants, as well as a larger zone of growth inhibition. MIC determination showed that the recA strain is more sensitive to ciprofloxacin (MIC = 0.007 μg/ml) than the wild-type strain.

We conducted a quantitative analysis of the PrecA-lux expression in the absence (control) and presence of ciprofloxacin and amikacin (Fig. 2A). Saturated cultures were diluted 1:10,000 in MH medium, incubated at 37°C with shaking until reaching an OD600 of ∼0.3. At this point, antibiotics were added, and cells were incubated for 4 h at 37°C. One-hundred-microliter aliquots of these cultures were withdrawn to measure both luciferase activity and OD600 using the GloMax-Multi+ microplate multimode reader detector (Promega, USA). We noted a 9-fold increase in recA expression after treatment with ciprofloxacin and no change in the presence of amikacin. Nevertheless, the combined treatment with ciprofloxacin plus amikacin promotes only a 3.8-fold increase in recA expression. Therefore, SOS induction by ciprofloxacin is reduced by more than 2-fold due to the presence of amikacin in liquid medium. Additionally, growth was monitored in the same conditions during the 4-h treatment. Growth yields presented the following OD600 values after 4 h of growth: 4.8 (MH without any antibiotic), 3.9 (AMI), 1.9 (CIP), and 1.5 (CIP+AMI) (data not show). The small reduction in growth yield in the presence of CIP+AMI compared to CIP alone indicates that the reduction in recA expression was not caused by an effect on growth.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Quantitative analysis of amikacin's effect on the SOS response. (A) The luminescence activity of PrecA-lux values was normalized by the optical density of the cultures (Lux/OD600), and the results shown represent the fold change compared to control (no antibiotic) after 4 h of treatment. *, significant difference between CIP and CIP+AMI (t test; P < 0.05). Error bars represent the mean ± standard deviation of three independent determinations. Fosr (B) and Rifr (C) mutant frequencies after treatment with different antibiotics. Data shown represent the mean mutant frequencies of 30 cultures from three independent experiments, and the error bars show the standard error. Asterisks indicate the significant difference between CIP and CIP+AMI treatments determined by the Mann-Whitney rank sum test with a P value of ≤0.05.

Next, we investigated the mutagenic effects of exposure to ciprofloxacin, amikacin, and a combination of both in P. aeruginosa PAO1 by scoring the appearance of rifampin and fosfomycin-resistant mutants (Rifr and Fosr) (Fig. 2B and C). After 4 h of treatment as described above, 2.5 ml of these cultures was centrifuged, resuspended in 5 ml of fresh MH medium, and cultivated overnight. Mutant frequencies were calculated as the total number of resistant colonies per viable cells in each culture. Cells treated with ciprofloxacin present 5.5-fold and 6.9-fold increases in the frequency of Fosr and Rifr mutants, respectively, compared to the nontreated control. Treatment with amikacin alone did not increase the mutant frequency in both markers. However, when both antibiotics were added, the mutant frequency decreases to 1.9-fold/2-fold (Fosr/Rifr) compared to the nontreated control. Thus, mutagenesis was increased by treatment with ciprofloxacin, but this effect is counteracted by the presence of amikacin.

Studies in E. coli showed that fluoroquinolones, β-lactams, trimethoprim, and sulfamethoxazole induce recA expression, whereas aminoglycosides, tetracycline, and chloramphenicol do not (11). However, in Vibrio cholerae, Klebsiella pneumoniae, and Photorhabdus luminescens, sub-MICs of aminoglycosides induce SOS-dependent promoters (22, 23). Here, we confirmed that ciprofloxacin induces the recA promoter activity in P. aeruginosa and reported the inhibitory effect of amikacin on this induction, which causes a decrease in mutagenesis.

The search for drugs that can prevent SOS induction is of considerable interest since suppression of this response may reduce the emergence of antibiotic-resistant bacteria. Examples of suppressors of the SOS response induced by fluoroquinolones were reported in Gram-positive and Gram-negative bacteria, such as the polyphenols baicalein (24), curcumin (25), and suramin (polysulphonated naphthylurea) (26), which have the ability to disassemble RecA single-stranded DNA filaments. Novobiocin blocks the ATP-binding site of the GyrB and inhibits ciprofloxacin and UV-induced SOS response (27, 28). The small-molecule N6-(1-naphthyl)-ADP acts as an ATP competitor, which prevents the formation of the RecA-DNA filament that is essential for all RecA-associated functions (29). Interestingly, sublethal concentrations of amikacin prevent FtsZ polymerization in E. coli (30), and perhaps the same phenomenon could happen with RecA nucleofilaments. The nature of amikacin-mediated inhibition of recA expression and mutagenesis is still not known, and future studies are still needed.

Treatment of P. aeruginosa clinical isolates with ciprofloxacin in combination with amikacin or gentamicin showed either synergistic, additive, or indifferent effects (31–33). Our results with the PAO1 strain are consistent with these previous observations since we observed no antagonistic effect of the ciprofloxacin-amikacin combination. In this regard, such a combined therapy may be used with the goal of inhibiting the SOS response and the development of resistance through mutagenesis.

ACKNOWLEDGMENTS

We thank Nilton Lincopan from the Department of Microbiology of the University of Sao Paulo, São Paulo, Brazil for his support, comments, and suggestions.

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (FAPESP; grant 2014/15982-6), and Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq; grant 407259/2013-9).

E.Y.V. was funded by a postdoctoral fellowship from CNPq (grant 151264/2014-7). J.B. was supported by Plan Nacional de I+D+i and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), cofinanced by the European Regional Development Fund (ERDF) “A way to achieve Europe” and grant FIS PI13/00063.

FOOTNOTES

    • Received 29 September 2016.
    • Returned for modification 30 October 2016.
    • Accepted 19 December 2016.
    • Accepted manuscript posted online 28 December 2016.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Rodríguez-Rojas A,
    2. Rodríguez-Beltrán J,
    3. Couce A,
    4. Blázquez J
    . 2013. Antibiotics and antibiotic resistance: a bitter fight against evolution. Int J Med Microbiol303:293–297. doi:10.1016/j.ijmm.2013.02.004.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Blázquez J,
    2. Couce A,
    3. Rodríguez-Beltrán J,
    4. Rodríguez-Rojas A
    . 2012. Antimicrobials as promoters of genetic variation. Curr Opin Microbiol15:561–569. doi:10.1016/j.mib.2012.07.007.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Power EGM,
    2. Phillips I
    . 1992. Induction of the SOS gene (umuC) by 4-quinolone antibacterial drugs. J Med Microbiol36:78–82. doi:10.1099/00222615-36-2-78.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Cirz RT,
    2. O'Neill BM,
    3. Hammond JA,
    4. Head SR,
    5. Romesberg FE
    . 2006. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J Bacteriol188:7101–7110. doi:10.1128/JB.00807-06.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Blázquez J,
    2. Gómez-Gómez J-M,
    3. Oliver A,
    4. Juan C,
    5. Kapur V,
    6. Martín S
    . 2006. PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol Microbiol62:84–99. doi:10.1111/j.1365-2958.2006.05366.x.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Drlica K,
    2. Zhao X
    . 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev61:377–392.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Drlica K,
    2. Malik M,
    3. Kerns RJ,
    4. Zhao X
    . 2008. Quinolone-mediated bacterial death. Antimicrob Agents Chemother52:385–392. doi:10.1128/AAC.01617-06.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Sanders LH,
    2. Rockel A,
    3. Lu H,
    4. Wozniak DJ,
    5. Sutton MD
    . 2006. Role of Pseudomonas aeruginosa dinB-encoded DNA polymerase IV in mutagenesis. J Bacteriol188:8573–8585. doi:10.1128/JB.01481-06.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Galhardo RS,
    2. Rocha RP,
    3. Marques MV,
    4. Menck CFM
    . 2005. An SOS-regulated operon involved in damage-inducible mutagenesis in Caulobacter crescentus. Nucleic Acids Res33:2603–2614. doi:10.1093/nar/gki551.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Henderson-Begg SK,
    2. Livermore DM,
    3. Hall LMC
    . 2006. Effect of subinhibitory concentrations of antibiotics on mutation frequency in Streptococcus pneumoniae. J Antimicrob Chemother57:849–854. doi:10.1093/jac/dkl064.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Thi Do T,
    2. López E,
    3. Rodríguez-Rojas A,
    4. Rodríguez-Beltrán J,
    5. Couce A,
    6. Guelfo JR,
    7. Castañeda-García A,
    8. Blázquez J
    . 2011. Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. J Antimicrob Chemother66:531–538. doi:10.1093/jac/dkq496.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Damron FH,
    2. McKenney ES,
    3. Barbier M,
    4. Liechti GW,
    5. Schweizer HP,
    6. Goldberg JB
    . 2013. Construction of mobilizable mini-Tn7 vectors for bioluminescent detection of gram-negative bacteria and single-copy promoter lux reporter analysis. Appl Environ Microbiol79:4149–4153. doi:10.1128/AEM.00640-13.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Krause KM,
    2. Serio AW,
    3. Kane TR,
    4. Connolly LE
    . 2016. Aminoglycosides: an overview. Cold Spring Harb Perspect Med6:a027029. doi:10.1101/cshperspect.a027029.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Fourmy D,
    2. Recht MI,
    3. Blanchard SC,
    4. Puglisi JD
    . 1996. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science274:1367–1371. doi:10.1126/science.274.5291.1367.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Borovinskaya MA,
    2. Pai RD,
    3. Zhang W,
    4. Schuwirth BS,
    5. Holton JM,
    6. Hirokawa G,
    7. Kaji H,
    8. Kaji A,
    9. Cate JHD
    . 2007. Structural basis for aminoglycoside inhibition of bacterial ribosome recycling. Nat Struct Mol Biol14:727–732. doi:10.1038/nsmb1271.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Odds FC
    . 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother52:1. doi:10.1093/jac/dkg301.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute,Wayne, PA.
  18. 18.↵
    1. Breidenstein EBM,
    2. Bains M,
    3. Hancock REW
    . 2012. Involvement of the lon protease in the SOS response triggered by ciprofloxacin in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother56:2879–2887. doi:10.1128/AAC.06014-11.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Aranda J,
    2. Bardina C,
    3. Beceiro A,
    4. Rumbo S,
    5. Cabral MP,
    6. Barbe J,
    7. Bou G
    . 2011. Acinetobacter baumannii RecA protein in repair of DNA damage, antimicrobial resistance, general stress response, and virulence. J Bacteriol193:3740–3747. doi:10.1128/JB.00389-11.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Singh R,
    2. Ledesma KR,
    3. Chang KT,
    4. Tam VH
    . 2010. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother54:4262–4268. doi:10.1128/AAC.00168-10.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Alexeyev MF
    . 1999. The pKNOCK series of broad-host-range mobilizable suicide vectors for gene knockout and targeted DNA insertion into the chromosome of Gram-negative bacteria. Biotechniques26:824–826.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Baharoglu Z,
    2. Krin E,
    3. Mazel D
    . 2013. RpoS plays a central role in the SOS induction by sub-lethal aminoglycoside concentrations in Vibrio cholerae. PLoS Genet9:e1003421. doi:10.1371/journal.pgen.1003421.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Baharoglu Z,
    2. Mazel D
    . 2011. Vibrio cholerae triggers SOS and mutagenesis in response to a wide range of antibiotics: a route towards multiresistance. Antimicrob Agents Chemother55:2438–2441. doi:10.1128/AAC.01549-10.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Peng Q,
    2. Zhou S,
    3. Yao F,
    4. Hou B,
    5. Huang Y,
    6. Hua D,
    7. Zheng Y,
    8. Qian Y
    . 2011. Baicalein suppresses the SOS response system of Staphylococcus aureus induced by ciprofloxacin. Cell Physiol Biochem28:1045–1050. doi:10.1159/000335791.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Bellio P,
    2. Brisdelli F,
    3. Perilli M,
    4. Sabatini A,
    5. Bottoni C,
    6. Segatore B,
    7. Setacci D,
    8. Amicosante G,
    9. Celenza G
    . 2014. Curcumin inhibits the SOS response induced by levofloxacin in Escherichia coli. Phytomedicine21:430–434. doi:10.1016/j.phymed.2013.10.011.
    OpenUrlCrossRef
  26. 26.↵
    1. Nautiyal A,
    2. Patil KN,
    3. Muniyappa K
    . 2014. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery. J Antimicrob Chemother69:1834–1843. doi:10.1093/jac/dku080.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Jara LM,
    2. Pérez-Varela M,
    3. Corral J,
    4. Arch M,
    5. Cortés P,
    6. Bou G,
    7. Aranda J,
    8. Barbé J
    . 2015. Novobiocin inhibits the antimicrobial resistance acquired through DNA damage-induced mutagenesis in Acinetobacter baumannii. Antimicrob Agents Chemother60:637–639. doi:10.1128/AAC.01810-15.
    OpenUrlCrossRef
  28. 28.↵
    1. Schröder W,
    2. Goerke C,
    3. Wolz C
    . 2013. Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus. J Antimicrob Chemother68:529–538. doi:10.1093/jac/dks456.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Lee AM,
    2. Ross CT,
    3. Zeng BB,
    4. Singleton SF
    . 2005. A molecular target for suppression of the evolution of antibiotic resistance: inhibition of the Escherichia coli RecA protein by N(6)-(1-naphthyl)-ADP. J Med Chem48:5408–5411. doi:10.1021/jm050113z.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Possoz C,
    2. Newmark J,
    3. Sorto N,
    4. Sherratt DJ,
    5. Tolmasky ME
    . 2007. Sublethal concentrations of the aminoglycoside amikacin interfere with cell division without affecting chromosome dynamics. Antimicrob Agents Chemother51:252–256. doi:10.1128/AAC.00892-06.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Sood P,
    2. Mandal A,
    3. Mishra B
    . 2000. Postantibiotic effect of a combination of antimicrobial agents on Pseudomonas aeruginosa. Chemotherapy46:173–176. doi:10.1159/000007274.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Drago L,
    2. De Vecchi E,
    3. Nicola L,
    4. Colombo A,
    5. Guerra A,
    6. Gismondo MR
    . 2004. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy50:202–210. doi:10.1159/000081033.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Gad GF,
    2. Mohamed HA,
    3. Ashour HM
    . 2011. Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt. PLoS One6:e17224. doi:10.1371/journal.pone.0017224.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in Pseudomonas aeruginosa
Estela Ynés Valencia, Fernanda Esposito, Beny Spira, Jesús Blázquez, Rodrigo S. Galhardo
Antimicrobial Agents and Chemotherapy Feb 2017, 61 (3) e02107-16; DOI: 10.1128/AAC.02107-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in Pseudomonas aeruginosa
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ciprofloxacin-Mediated Mutagenesis Is Suppressed by Subinhibitory Concentrations of Amikacin in Pseudomonas aeruginosa
Estela Ynés Valencia, Fernanda Esposito, Beny Spira, Jesús Blázquez, Rodrigo S. Galhardo
Antimicrobial Agents and Chemotherapy Feb 2017, 61 (3) e02107-16; DOI: 10.1128/AAC.02107-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

amikacin
ciprofloxacin
mutation
Pseudomonas aeruginosa
Rec A Recombinases
Pseudomonas aeruginosa
SOS response
ciprofloxacin
recA

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596